跳至主要内容
临床试验/NCT00599287
NCT00599287终止3 期

Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients: a Randomized, Mono-blind Pilot Trial

UMC Utrecht1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2008年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
终止
发起方
UMC Utrecht
入组人数
80
试验地点
1
主要终点
duration of delirium

研究概览

简要总结

The purpose of this pilot-trial is the feasibility of a large randomized, placebo controlled, doubleblind clinical trial to investigate the use of methylphenidate, rivastigmine or haloperidol in hypoactive ICU-delirium. In addition we will compare duration of delirium, severity of delirium, length of ICU/hospital stay and side effects between the different interventions.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Older than 18 years
  • Diagnosed as hypoactive delirium
  • Informed consent given

排除标准

  • Pregnancy
  • M. Parkinson
  • Lewy-body dementia
  • Prolonged QT-time
  • Known allergy to the medicinals used
  • Renal replacement therapy
  • Hepatic encephalopathy
  • Hyperthyroid
  • Previous suicide attempts
  • Syndrome of Gilles de la Tourette
  • Patients which cannot receive the medication oral or through a nasogastric tube

研究组 & 干预措施

2

Experimental

Methylphenidate

干预措施: Methylphenidate (Drug)

3

Experimental

Rivastigmine

干预措施: Rivastigmine (Drug)

4

Experimental

Haloperidol

干预措施: Haloperidol (Drug)

结局指标

主要结局

duration of delirium

时间窗: Days

次要结局

  • delirium severity(duration of delirium)
  • frequency of side effects(duration of intervention)
  • duration of ICU-stay(days)
  • duration of in hospital stay(days)

研究者

发起方
UMC Utrecht
申办方类型
Other

研究点 (1)

Loading locations...

相似试验

Methylphenidate, Rivastigmine or Haloperidol in... | 临床试验